<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262911</url>
  </required_header>
  <id_info>
    <org_study_id>115083</org_study_id>
    <nct_id>NCT01262911</nct_id>
  </id_info>
  <brief_title>Effect of SRT2379 on Endotoxin-Induced Inflammation</brief_title>
  <official_title>A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtris, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic&#xD;
      inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice. The&#xD;
      objective of this study is to test if SRT2379 may be a novel compound for the treatment of&#xD;
      inflammatory disorders in man.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2011</start_date>
  <completion_date type="Actual">April 26, 2011</completion_date>
  <primary_completion_date type="Actual">April 26, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if a single dose of SRT2379 attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS).</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine PK of SRT2379 in normal healthy male subjects exposed to low-dose endotoxin (LPS).</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS).</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1.0 g SRT2379</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 1.0g of SRT2379</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 g Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of 1.0g of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRT2379</intervention_name>
    <description>SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.</description>
    <arm_group_label>1.0 g SRT2379</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.</description>
    <arm_group_label>1.0 g Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination and laboratory tests&#xD;
             carried out within 21 days prior to dosing.&#xD;
&#xD;
          -  Male between 18 and 35 years of age inclusive, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
          -  Chemistry panel, including renal and liver functions tests, without any clinically&#xD;
             relevant abnormality&#xD;
&#xD;
          -  Subjects must agree with their partners to use double-barrier birth control or&#xD;
             abstinence while participating in the study and for 7 days following the dose of study&#xD;
             drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has had a major illness in the past 3 months or any significant chronic&#xD;
             medical illness that the investigator would deem unfavorable for enrollment including&#xD;
             inflammatory diseases&#xD;
&#xD;
          -  Subjects with a history of any type of malignancy with the exception of successfully&#xD;
             treated basal cell cancer of the skin&#xD;
&#xD;
          -  Subject has a past or current gastrointestinal disease which may influence drug&#xD;
             absorption&#xD;
&#xD;
          -  The subject has a known positive test for hepatitis C antibody, hepatitis B surface&#xD;
             antigen or HIV&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          -  Subject has a history, within three years, of drug abuse (including benzodiazepines,&#xD;
             opioids, amphetamine, cocaine, THC) or a positive drug results at the Screening visit&#xD;
&#xD;
          -  History of alcoholism and/or is drinking more than 3 drinks per day. Alcoholism is&#xD;
             defined as an average weekly intake of &gt;21 units for males or &gt;14 units for females.&#xD;
             One unit is equivalent to 8 g of alcohol: a half-pint (~240 mL) of beer, 1 glass (125&#xD;
             mL) of wine or 1 (25 mL) measure of spirits&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within three months of the dosing in the current study&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, and herbal and dietary supplements&#xD;
             within 7 days unless in the opinion of the Investigator and Medical Monitor the&#xD;
             medication will not interfere with the study procedures or compromise subject safety&#xD;
&#xD;
          -  Subject has difficultly in donating blood or accessibility of a vein in left or right&#xD;
             arm&#xD;
&#xD;
          -  Subject has donated more than 350 mL of blood in last 3 months&#xD;
&#xD;
          -  Subject uses tobacco products&#xD;
&#xD;
          -  Any clinically relevant abnormality noted on the 12-lead ECG as judged by the&#xD;
             investigator or an average QTcB or QTcF &gt; 450 msec&#xD;
&#xD;
          -  Any other issue that, in the opinion of the Principal Investigator, would could be&#xD;
             harmful to the subject or compromise interpretation of the data&#xD;
&#xD;
          -  Prior participation in a trial where the subject received IV LPS&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115083</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

